Quarterly report · Q3
4483.TEDINET S100Q8QG
Period2022-04-01 → 2022-12-31
Filed2023-02-14
StandardIFRS
ConsolidatedYes
Data checks16 of 16 passed
Key figures · 61
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥19.5bn | 2022-04-01 → 2022-12-31 | Cons. | Revenue IFRS |
| Revenue | ¥7.5bn | 2022-10-01 → 2022-12-31d | Cons. | Revenue IFRS |
| Revenue | ¥21.8bn | 2021-04-01 → 2022-03-31 | Cons. | Revenue IFRS (5-year summary) |
| Revenue | ¥15.7bn | 2021-04-01 → 2021-12-31 | Cons. | Revenue IFRS |
| Revenue | ¥6.1bn | 2021-10-01 → 2021-12-31d | Cons. | Revenue IFRS |
| Operating income | ¥4.0bn | 2022-04-01 → 2022-12-31 | Cons. | Operating profit loss IFRS |
| Operating income | ¥1.8bn | 2022-10-01 → 2022-12-31d | Cons. | Operating profit loss IFRS |
| Operating income | ¥3.4bn | 2021-04-01 → 2021-12-31 | Cons. | Operating profit loss IFRS |
| Operating income | ¥1.7bn | 2021-10-01 → 2021-12-31d | Cons. | Operating profit loss IFRS |
| Profit before tax | ¥4.0bn | 2022-04-01 → 2022-12-31 | Cons. | Profit loss before tax IFRS |
| Profit before tax | ¥1.8bn | 2022-10-01 → 2022-12-31d | Cons. | Profit loss before tax IFRS |
| Profit before tax | ¥4.8bn | 2021-04-01 → 2022-03-31 | Cons. | Profit loss before tax IFRS (5-year summary) |
| Profit before tax | ¥3.4bn | 2021-04-01 → 2021-12-31 | Cons. | Profit loss before tax IFRS |
| Profit before tax | ¥1.7bn | 2021-10-01 → 2021-12-31d | Cons. | Profit loss before tax IFRS |
| Net income (owners) | ¥2.7bn | 2022-04-01 → 2022-12-31 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income (owners) | ¥1.2bn | 2022-10-01 → 2022-12-31d | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income (owners) | ¥3.2bn | 2021-04-01 → 2022-03-31 | Cons. | Profit loss attributable to owners of parent IFRS (5-year summary) |
| Net income (owners) | ¥2.3bn | 2021-04-01 → 2021-12-31 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income (owners) | ¥1.1bn | 2021-10-01 → 2021-12-31d | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income | ¥2.7bn | 2022-04-01 → 2022-12-31 | Cons. | Profit loss IFRS |
| Net income | ¥1.2bn | 2022-10-01 → 2022-12-31d | Cons. | Profit loss IFRS |
| Net income | ¥2.3bn | 2021-04-01 → 2021-12-31 | Cons. | Profit loss IFRS |
| Net income | ¥1.1bn | 2021-10-01 → 2021-12-31d | Cons. | Profit loss IFRS |
| Total assets | ¥95.1bn | at 2022-12-31 | Cons. | Assets IFRS |
| Total assets | ¥62.1bn | at 2022-03-31 | Cons. | Assets IFRS |
| Total assets | ¥60.4bn | at 2021-12-31 | Cons. | Total assets IFRS (5-year summary) |
| Total liabilities | ¥32.3bn | at 2022-12-31 | Cons. | Liabilities IFRS |
| Total liabilities | ¥30.9bn | at 2022-03-31 | Cons. | Liabilities IFRS |
| Net assets / equity | ¥62.9bn | at 2022-12-31 | Cons. | Equity IFRS |
| Net assets / equity | ¥31.2bn | at 2022-03-31 | Cons. | Equity IFRS |
| Net assets / equity | ¥30.1bn | at 2021-12-31 | Cons. | Equity IFRS |
| Net assets / equity | ¥28.3bn | at 2021-03-31d | Cons. | Equity IFRS |
| Equity (owners) | ¥62.9bn | at 2022-12-31 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥31.2bn | at 2022-03-31 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥30.1bn | at 2021-12-31 | Cons. | Equity attributable to owners of parent IFRS (5-year summary) |
| Cash & equivalents | ¥21.8bn | at 2022-12-31 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥13.2bn | at 2022-03-31 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥14.5bn | at 2021-12-31 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥19.9bn | at 2021-03-31d | Cons. | Cash and cash equivalents IFRS |
| Operating cash flow | ¥2.5bn | 2022-04-01 → 2022-12-31 | Cons. | Net cash provided by used in operating activities IFRS |
| Operating cash flow | ¥3.8bn | 2021-04-01 → 2022-03-31 | Cons. | Cash flows from used in operating activities IFRS (5-year summary) |
| Operating cash flow | ¥1.9bn | 2021-04-01 → 2021-12-31 | Cons. | Net cash provided by used in operating activities IFRS |
| Investing cash flow | −¥21.8bn | 2022-04-01 → 2022-12-31 | Cons. | Net cash provided by used in investing activities IFRS |
| Investing cash flow | −¥8.1bn | 2021-04-01 → 2022-03-31 | Cons. | Cash flows from used in investing activities IFRS (5-year summary) |
| Investing cash flow | −¥5.3bn | 2021-04-01 → 2021-12-31 | Cons. | Net cash provided by used in investing activities IFRS |
| Financing cash flow | ¥27.9bn | 2022-04-01 → 2022-12-31 | Cons. | Net cash provided by used in financing activities IFRS |
| Financing cash flow | −¥2.4bn | 2021-04-01 → 2022-03-31 | Cons. | Cash flows from used in financing activities IFRS (5-year summary) |
| Financing cash flow | −¥2.1bn | 2021-04-01 → 2021-12-31 | Cons. | Net cash provided by used in financing activities IFRS |
| EPS (basic) | ¥44.98 | 2022-04-01 → 2022-12-31 | Cons. | Basic earnings loss per share IFRS |
| EPS (basic) | ¥19.28 | 2022-10-01 → 2022-12-31d | Cons. | Basic earnings loss per share IFRS |
| EPS (basic) | ¥57.74 | 2021-04-01 → 2022-03-31 | Cons. | Basic earnings loss per share IFRS (5-year summary) |
| EPS (basic) | ¥40.46 | 2021-04-01 → 2021-12-31 | Cons. | Basic earnings loss per share IFRS |
| EPS (basic) | ¥20.16 | 2021-10-01 → 2021-12-31d | Cons. | Basic earnings loss per share IFRS |
| EPS (diluted) | ¥42.66 | 2022-04-01 → 2022-12-31 | Cons. | Diluted earnings loss per share IFRS |
| EPS (diluted) | ¥18.45 | 2022-10-01 → 2022-12-31d | Cons. | Diluted earnings loss per share IFRS |
| EPS (diluted) | ¥54.16 | 2021-04-01 → 2022-03-31 | Cons. | Diluted earnings loss per share IFRS (5-year summary) |
| EPS (diluted) | ¥38.14 | 2021-04-01 → 2021-12-31 | Cons. | Diluted earnings loss per share IFRS |
| EPS (diluted) | ¥18.99 | 2021-10-01 → 2021-12-31d | Cons. | Diluted earnings loss per share IFRS |
| Equity ratio | 66.1% | at 2022-12-31 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 50.2% | at 2022-03-31 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 49.9% | at 2021-12-31 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 72
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | revenue | 2022-04-01 → 2022-12-31 | −¥189m |
| Reconciling Itemsreconciling | revenue | 2022-10-01 → 2022-12-31 | −¥62m |
| Reconciling Itemsreconciling | revenue intersegment | 2022-04-01 → 2022-12-31 | −¥189m |
| Reconciling Itemsreconciling | revenue intersegment | 2022-10-01 → 2022-12-31 | −¥62m |
| Reconciling Itemsreconciling | segment profit | 2022-04-01 → 2022-12-31 | −¥417m |
| Reconciling Itemsreconciling | segment profit | 2022-10-01 → 2022-12-31 | −¥227m |
| jpcrp040300-q3r_E35308-000Dispensing Pharmacy Supportreportable segment | revenue | 2022-04-01 → 2022-12-31 | ¥2.8bn |
| jpcrp040300-q3r_E35308-000Dispensing Pharmacy Supportreportable segment | revenue | 2022-10-01 → 2022-12-31 | ¥944m |
| jpcrp040300-q3r_E35308-000Dispensing Pharmacy Supportreportable segment | revenue external | 2022-04-01 → 2022-12-31 | ¥2.7bn |
| jpcrp040300-q3r_E35308-000Dispensing Pharmacy Supportreportable segment | revenue external | 2022-10-01 → 2022-12-31 | ¥901m |
| jpcrp040300-q3r_E35308-000Dispensing Pharmacy Supportreportable segment | revenue intersegment | 2022-04-01 → 2022-12-31 | ¥127m |
| jpcrp040300-q3r_E35308-000Dispensing Pharmacy Supportreportable segment | revenue intersegment | 2022-10-01 → 2022-12-31 | ¥43m |
| jpcrp040300-q3r_E35308-000Dispensing Pharmacy Supportreportable segment | segment profit | 2022-04-01 → 2022-12-31 | ¥310m |
| jpcrp040300-q3r_E35308-000Dispensing Pharmacy Supportreportable segment | segment profit | 2022-10-01 → 2022-12-31 | ¥118m |
| jpcrp040300-q3r_E35308-000Healthcare Big Datareportable segment | revenue | 2022-04-01 → 2022-12-31 | ¥13.1bn |
| jpcrp040300-q3r_E35308-000Healthcare Big Datareportable segment | revenue | 2022-10-01 → 2022-12-31 | ¥5.2bn |
| jpcrp040300-q3r_E35308-000Healthcare Big Datareportable segment | revenue external | 2022-04-01 → 2022-12-31 | ¥13.1bn |
| jpcrp040300-q3r_E35308-000Healthcare Big Datareportable segment | revenue external | 2022-10-01 → 2022-12-31 | ¥5.2bn |
| jpcrp040300-q3r_E35308-000Healthcare Big Datareportable segment | revenue intersegment | 2022-04-01 → 2022-12-31 | ¥62m |
| jpcrp040300-q3r_E35308-000Healthcare Big Datareportable segment | revenue intersegment | 2022-10-01 → 2022-12-31 | ¥19m |
| jpcrp040300-q3r_E35308-000Healthcare Big Datareportable segment | segment profit | 2022-04-01 → 2022-12-31 | ¥4.0bn |
| jpcrp040300-q3r_E35308-000Healthcare Big Datareportable segment | segment profit | 2022-10-01 → 2022-12-31 | ¥2.0bn |
| jpcrp040300-q3r_E35308-000Tele Medicinereportable segment | revenue | 2022-04-01 → 2022-12-31 | ¥3.8bn |
| jpcrp040300-q3r_E35308-000Tele Medicinereportable segment | revenue | 2022-10-01 → 2022-12-31 | ¥1.4bn |
| jpcrp040300-q3r_E35308-000Tele Medicinereportable segment | revenue external | 2022-04-01 → 2022-12-31 | ¥3.8bn |
| jpcrp040300-q3r_E35308-000Tele Medicinereportable segment | revenue external | 2022-10-01 → 2022-12-31 | ¥1.4bn |
| jpcrp040300-q3r_E35308-000Tele Medicinereportable segment | segment profit | 2022-04-01 → 2022-12-31 | ¥1.4bn |
| jpcrp040300-q3r_E35308-000Tele Medicinereportable segment | segment profit | 2022-10-01 → 2022-12-31 | ¥492m |
| —segment total | revenue | 2022-04-01 → 2022-12-31 | ¥19.7bn |
| —segment total | revenue | 2022-10-01 → 2022-12-31 | ¥7.5bn |
| —segment total | revenue external | 2022-04-01 → 2022-12-31 | ¥19.5bn |
| —segment total | revenue external | 2022-10-01 → 2022-12-31 | ¥7.5bn |
| —segment total | revenue intersegment | 2022-04-01 → 2022-12-31 | ¥189m |
| —segment total | revenue intersegment | 2022-10-01 → 2022-12-31 | ¥62m |
| —segment total | segment profit | 2022-04-01 → 2022-12-31 | ¥5.7bn |
| —segment total | segment profit | 2022-10-01 → 2022-12-31 | ¥2.6bn |
| Reconciling Itemsreconciling | revenue | 2021-04-01 → 2021-12-31 | −¥143m |
| Reconciling Itemsreconciling | revenue | 2021-10-01 → 2021-12-31 | −¥54m |
| Reconciling Itemsreconciling | revenue intersegment | 2021-04-01 → 2021-12-31 | −¥143m |
| Reconciling Itemsreconciling | revenue intersegment | 2021-10-01 → 2021-12-31 | −¥54m |
| Reconciling Itemsreconciling | segment profit | 2021-04-01 → 2021-12-31 | −¥242m |
| Reconciling Itemsreconciling | segment profit | 2021-10-01 → 2021-12-31 | −¥85m |
| jpcrp040300-q3r_E35308-000Dispensing Pharmacy Supportreportable segment | revenue | 2021-04-01 → 2021-12-31 | ¥2.6bn |
| jpcrp040300-q3r_E35308-000Dispensing Pharmacy Supportreportable segment | revenue | 2021-10-01 → 2021-12-31 | ¥907m |
| jpcrp040300-q3r_E35308-000Dispensing Pharmacy Supportreportable segment | revenue external | 2021-04-01 → 2021-12-31 | ¥2.5bn |
| jpcrp040300-q3r_E35308-000Dispensing Pharmacy Supportreportable segment | revenue external | 2021-10-01 → 2021-12-31 | ¥873m |
| jpcrp040300-q3r_E35308-000Dispensing Pharmacy Supportreportable segment | revenue intersegment | 2021-04-01 → 2021-12-31 | ¥90m |
| jpcrp040300-q3r_E35308-000Dispensing Pharmacy Supportreportable segment | revenue intersegment | 2021-10-01 → 2021-12-31 | ¥34m |
| jpcrp040300-q3r_E35308-000Dispensing Pharmacy Supportreportable segment | segment profit | 2021-04-01 → 2021-12-31 | ¥209m |
| jpcrp040300-q3r_E35308-000Dispensing Pharmacy Supportreportable segment | segment profit | 2021-10-01 → 2021-12-31 | ¥46m |
| jpcrp040300-q3r_E35308-000Healthcare Big Datareportable segment | revenue | 2021-04-01 → 2021-12-31 | ¥9.9bn |
| jpcrp040300-q3r_E35308-000Healthcare Big Datareportable segment | revenue | 2021-10-01 → 2021-12-31 | ¥4.1bn |
| jpcrp040300-q3r_E35308-000Healthcare Big Datareportable segment | revenue external | 2021-04-01 → 2021-12-31 | ¥9.8bn |
| jpcrp040300-q3r_E35308-000Healthcare Big Datareportable segment | revenue external | 2021-10-01 → 2021-12-31 | ¥4.0bn |
| jpcrp040300-q3r_E35308-000Healthcare Big Datareportable segment | revenue intersegment | 2021-04-01 → 2021-12-31 | ¥52m |
| jpcrp040300-q3r_E35308-000Healthcare Big Datareportable segment | revenue intersegment | 2021-10-01 → 2021-12-31 | ¥20m |
| jpcrp040300-q3r_E35308-000Healthcare Big Datareportable segment | segment profit | 2021-04-01 → 2021-12-31 | ¥3.4bn |
| jpcrp040300-q3r_E35308-000Healthcare Big Datareportable segment | segment profit | 2021-10-01 → 2021-12-31 | ¥1.7bn |
| jpcrp040300-q3r_E35308-000Tele Medicinereportable segment | revenue | 2021-04-01 → 2021-12-31 | ¥3.4bn |
| jpcrp040300-q3r_E35308-000Tele Medicinereportable segment | revenue | 2021-10-01 → 2021-12-31 | ¥1.2bn |
| jpcrp040300-q3r_E35308-000Tele Medicinereportable segment | revenue external | 2021-04-01 → 2021-12-31 | ¥3.4bn |
| jpcrp040300-q3r_E35308-000Tele Medicinereportable segment | revenue external | 2021-10-01 → 2021-12-31 | ¥1.2bn |
| jpcrp040300-q3r_E35308-000Tele Medicinereportable segment | segment profit | 2021-04-01 → 2021-12-31 | ¥1.2bn |
| jpcrp040300-q3r_E35308-000Tele Medicinereportable segment | segment profit | 2021-10-01 → 2021-12-31 | ¥470m |
| —segment total | revenue | 2021-04-01 → 2021-12-31 | ¥15.8bn |
| —segment total | revenue | 2021-10-01 → 2021-12-31 | ¥6.2bn |
| —segment total | revenue external | 2021-04-01 → 2021-12-31 | ¥15.7bn |
| —segment total | revenue external | 2021-10-01 → 2021-12-31 | ¥6.1bn |
| —segment total | revenue intersegment | 2021-04-01 → 2021-12-31 | ¥143m |
| —segment total | revenue intersegment | 2021-10-01 → 2021-12-31 | ¥54m |
| —segment total | segment profit | 2021-04-01 → 2021-12-31 | ¥4.8bn |
| —segment total | segment profit | 2021-10-01 → 2021-12-31 | ¥2.2bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 842
| Item | Context | Value | Unit |
|---|---|---|---|
| Profit loss before tax IFRS | Prior1QuarterDuration | 1681000000 | JPY |
| Profit loss before tax IFRS | CurrentQuarterDuration | 1773000000 | JPY |
| Income tax expense IFRS | Prior1QuarterDuration | 546000000 | JPY |
| Income tax expense IFRS | CurrentQuarterDuration | 554000000 | JPY |
| Profit loss IFRS | Prior1QuarterDuration | 1134000000 | JPY |
| Profit loss IFRS | CurrentQuarterDuration | 1218000000 | JPY |
| Profit loss attributable to owners of parent IFRS | Prior1QuarterDuration | 1135000000 | JPY |
| Profit loss attributable to owners of parent IFRS | CurrentQuarterDuration | 1210000000 | JPY |
| Profit loss attributable to non controlling interests IFRS | Prior1QuarterDuration | -1000000 | JPY |
| Profit loss attributable to non controlling interests IFRS | CurrentQuarterDuration | 8000000 | JPY |
| Profit loss IFRS | Prior1QuarterDuration | 1134000000 | JPY |
| Profit loss IFRS | CurrentQuarterDuration | 1218000000 | JPY |
| Basic earnings loss per share IFRS | Prior1QuarterDuration | 20.16 | |
| Basic earnings loss per share IFRS | CurrentQuarterDuration | 19.28 | |
| Diluted earnings loss per share IFRS | Prior1QuarterDuration | 18.99 | |
| Diluted earnings loss per share IFRS | CurrentQuarterDuration | 18.45 | |
| Profit loss IFRS | Prior1YTDDuration | 2271000000 | JPY |
| Profit loss IFRS | CurrentYTDDuration | 2655000000 | JPY |
| Net change in fair value of equity instruments designated as measured at fair value through other comprehensive income net of tax items that will not be reclassified to profit or loss oci IFRS | Prior1YTDDuration | 1000000 | JPY |
| Net change in fair value of equity instruments designated as measured at fair value through other comprehensive income net of tax items that will not be reclassified to profit or loss oci IFRS | CurrentYTDDuration | 3000000 | JPY |
| Total of items that will not be reclassified to profit or loss oci IFRS | Prior1YTDDuration | 1000000 | JPY |
| Total of items that will not be reclassified to profit or loss oci IFRS | CurrentYTDDuration | 3000000 | JPY |
| Exchange differences on translation of foreign operations net of tax items that may be reclassified to profit or loss oci IFRS | Prior1YTDDuration | -1000000 | JPY |
| Exchange differences on translation of foreign operations net of tax items that may be reclassified to profit or loss oci IFRS | CurrentYTDDuration | 0 | JPY |
| Total of items that may be reclassified to profit or loss oci IFRS | Prior1YTDDuration | -1000000 | JPY |
| Total of items that may be reclassified to profit or loss oci IFRS | CurrentYTDDuration | 0 | JPY |
| Other comprehensive income IFRS | Prior1YTDDuration | -0 | JPY |
| Other comprehensive income IFRS | CurrentYTDDuration | 3000000 | JPY |
| Comprehensive income IFRS | Prior1YTDDuration | 2271000000 | JPY |
| Comprehensive income IFRS | CurrentYTDDuration | 2659000000 | JPY |
| Comprehensive income attributable to owners of parent IFRS | Prior1YTDDuration | 2272000000 | JPY |
| Comprehensive income attributable to owners of parent IFRS | CurrentYTDDuration | 2658000000 | JPY |
| Comprehensive income attributable to non controlling interests IFRS | Prior1YTDDuration | -0 | JPY |
| Comprehensive income attributable to non controlling interests IFRS | CurrentYTDDuration | 0 | JPY |
| Comprehensive income IFRS | Prior1YTDDuration | 2271000000 | JPY |
| Comprehensive income IFRS | CurrentYTDDuration | 2659000000 | JPY |
| Profit loss IFRS | Prior1QuarterDuration | 1134000000 | JPY |
| Profit loss IFRS | CurrentQuarterDuration | 1218000000 | JPY |
| Net change in fair value of equity instruments designated as measured at fair value through other comprehensive income net of tax items that will not be reclassified to profit or loss oci IFRS | Prior1QuarterDuration | 0 | JPY |
| Net change in fair value of equity instruments designated as measured at fair value through other comprehensive income net of tax items that will not be reclassified to profit or loss oci IFRS | CurrentQuarterDuration | -3000000 | JPY |
| Total of items that will not be reclassified to profit or loss oci IFRS | Prior1QuarterDuration | 0 | JPY |
| Total of items that will not be reclassified to profit or loss oci IFRS | CurrentQuarterDuration | -3000000 | JPY |
| Exchange differences on translation of foreign operations net of tax items that may be reclassified to profit or loss oci IFRS | Prior1QuarterDuration | -0 | JPY |
| Exchange differences on translation of foreign operations net of tax items that may be reclassified to profit or loss oci IFRS | CurrentQuarterDuration | 1000000 | JPY |
| Total of items that may be reclassified to profit or loss oci IFRS | Prior1QuarterDuration | -0 | JPY |
| Total of items that may be reclassified to profit or loss oci IFRS | CurrentQuarterDuration | 1000000 | JPY |
| Other comprehensive income IFRS | Prior1QuarterDuration | 0 | JPY |
| Other comprehensive income IFRS | CurrentQuarterDuration | -2000000 | JPY |
| Comprehensive income IFRS | Prior1QuarterDuration | 1135000000 | JPY |
| Comprehensive income IFRS | CurrentQuarterDuration | 1216000000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 16 of 16 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |